AJ Rice, UBS: Asked about patient care cost growth outside of phosphate binders. Ackerman noted a 3.75% anticipated growth in historical costs, primarily from labor and other expenses. Pito ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism ...

Owing to its novel mechanism of action, tenapanor can be used in combination with phosphate binders to further significantly reduce serum phosphate levels and improve the rate of achieving target ...